This segment focuses on the development and clinical evaluation of bel-sar, a virus-like drug conjugate (VDC), for the treatment of primary choroidal melanoma (PCM) and other ocular oncology indications. Research and development activities include Phase 3 clinical trials (COMPASS) to assess the efficacy and safety of bel-sar in PCM patients. The technology utilizes VDCs to precisely target cancer cells while sparing healthy tissue, aiming to preserve vision and organ function. Patient impact is significant, offering a potential vision-sparing treatment option for a disease with limited treatment options. Market positioning is strong due to the unmet medical need and the innovative approach. Future opportunities include expanding bel-sar's application to other ocular cancers and exploring combination therapies. Regulatory and clinical aspects involve ongoing interactions with regulatory bodies like the FDA. Partnerships and collaborations are crucial for clinical trial execution and commercialization.

This segment centers on the application of bel-sar in the treatment of bladder cancer, specifically non-muscle invasive bladder cancer (NMIBC). Research and development efforts include Phase 1 clinical trials to assess the safety and efficacy of bel-sar in this indication. The technology leverages VDCs to target cancer cells within the bladder, potentially offering an alternative to the current standard of care, Bacillus Calmette-Guérin (BCG) therapy. The patient impact is substantial, providing a potential new treatment option for patients who have failed or are intolerant to BCG. Market positioning is driven by the need for improved therapies in bladder cancer. Future opportunities include expanding clinical trials to later-stage bladder cancer and exploring combination therapies. Regulatory and clinical aspects involve navigating the regulatory pathway for bladder cancer indications. Partnerships and collaborations are essential for clinical trial execution and commercialization.